Somatropin - Merck Serono

Drug Profile

Somatropin - Merck Serono

Alternative Names: r-hGH; Saizen; Serostim; SJ 0011; Zorbtive

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merck Serono
  • Developer Bioject; Merck Serono; Savient Pharmaceuticals
  • Class Growth hormones; Hormonal replacements
  • Mechanism of Action Intercellular signalling peptide and protein stimulants; Somatotropin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cachexia; Short bowel syndrome; Lipodystrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cachexia; Growth disorders; Short bowel syndrome; Short stature; Somatotropin deficiency
  • Phase III Female infertility
  • Discontinued Lipodystrophy

Most Recent Events

  • 08 May 2015 AEterna Zentaris and ASCEND therapeutics agree to promote somatropin in USA
  • 01 May 2015 EMD Serono completes a phase II trial in Female infertility (Adjunctive treatment) in Canada (NCT01204840)
  • 14 Oct 2013 Savient Pharmaceuticals files for Chapter 11 bankruptcy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top